Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of GW501516 in primary hypercholesterolemia
2006-002911-28Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GW501516 in hypercholesterolemia (4 arms), sponsored by GSK. Primary endpoint: Percentage change from baseline in LDL cholesterol. Started Jul 2006; status: completed.
02
Drugs
GW501516
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2006-002911-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002911-28.